Zevra Therapeutics, Inc. (KMPH)

Evaluation: Based on all recent filings, financial statements, and news.

See full evaluation
Ask a question about Zevra Therapeutics, Inc. (KMPH)
Company Performance

Current Price

as of Oct 16, 2024

$8.46

P/E Ratio

N/A

Market Cap

$445.15M

Description

Zevra Therapeutics, Inc. is a commercial-stage rare disease company that combines science, data and patient needs to create therapies for diseases with limited or no treatment options. The firm focuses on the treatment of rare neurological and sleep conditions such as certain Urea Cycle Disorders, Niemann Pick Disease Type C and Idiopathic Hypersomnia. The company receives royalties for AZSTARYS from its commercial partner Corium. The company was founded by Christal M. M. Mickle and Travis C. Mickle on October 30, 2006 and is headquartered in Celebration, FL.

Metrics

Overview

  • HQCelebration, FL
  • SectorHealth Technology
  • IndustryPharmaceuticals: Major
  • TickerKMPH
  • Price$8.46+0.95%

Trading Information

  • Market Cap$445.15M
  • Float99.39%
  • Average Daily Volume (1m)1,374,778
  • Average Daily Volume (3m)1,126,898
  • EPS-$1.68

Company

  • Revenue$23.99M
  • Rev Growth (1yr)-47.47%
  • Net Income-$19.93M
  • Gross Margin-50.17%
  • EBITDA Margin-499.73%
  • EBITDA-$22.23M
  • EV$225.51M
  • EV/Revenue9.40
  • P/EN/A
  • P/S14.78
  • P/B10.94